Physician profile
Daniel Silvershein
NPI 1932123213
$1,841.02
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $19.24 · 2022: $24.41 · 2024: $20.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.80 | 2019 | |
| Gilead Sciences, INC. | $142.94 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.86 | 2019 | |
| Amarin Pharma, INC. | $136.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.49 | 2019 | |
| Lilly USA, LLC | $106.91 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $106.73 | 2019 | |
| Novo Nordisk INC | $103.62 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $102.88 | 2019 | |
| Pfizer INC. | $92.38 | 2019 | |
| Supernus Pharmaceuticals, INC. | $70.47 | 2019 | |
| Merck Sharp & Dohme LLC | $66.74 | 2019 | |
| Glaxosmithkline, LLC. | $59.24 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $51.50 | 2019 | |
| Janssen Biotech, INC. | $42.57 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $41.28 | 2019 | |
| Allergan, INC. | $33.67 | 2019-2020 | |
| Shire North American Group INC | $32.09 | 2019 | |
| Daiichi Sankyo INC. | $22.94 | 2019 | |
| Bioventus LLC | $21.90 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.55 | 2019 | |
| Vivus LLC | $19.45 | 2019 | |
| Mayne Pharma Commercial LLC | $19.38 | 2019 | |
| Amgen INC. | $19.05 | 2019 | |
| Sanofi Pasteur INC. | $18.53 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $14.97 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Silvershein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.